
Jonathan A. Bernstein FAAAAI, FACAAI, FACP, M.D.
Who Am I? – I was born and raised in Cincinnati, Ohio in a medical family. My father was I.Leonard Bernstein, the first board certified allergist in Cincinnati, the founder of Advanced Allergy Services and the University of Cincinnati Allergy Immunology Fellowship Program and Research laboratory. My early experiences working in my father’s medical practice and in his research laboratory, influenced me to become a physician. I attended Kenyon College in Gambier, Ohio where I received a BA as a chemistry major and then the University of Cincinnati College of Medicine where I received my Doctor of Medicine Diploma. It was there I met my wife of 41 years, Lisa. Together we have been blessed with 4 children and 6 grandchildren. After my Internal Medicine training at the Cleveland Clinic Foundation and Allergy Immunology fellowship at Northwestern University in Chicago, I returned to Cincinnati in 1990 as a faculty member of the University of Cincinnati Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology and began clinical practice at the Advanced Allergy Services with my father and brother, David, where we also conduct clinical research investigating novel therapeutic agents for a number of medical conditions. I am the current director of the University of Cincinnati Allergy laboratory where we conduct research on a spectrum of medical conditions including mast cell disorders, atopic dermatitis and environmental interventions for asthma management.
What are my credentials? I am a board-certified allergist immunologist and recertified. I have spent my career taking care of patients, educating medical students, residents and Allergy fellows and conducting research with over 500 publications that investigate or review a spectrum of topics in our specialty. I have been honored to be elected President of the Academy of Allergy, Asthma & Immunology (AAAAI) (2022-2023), the largest membership organization in the country with over 7,000 allergists and am the current chair of the AAAAI Foundation. In addition, I have been actively involved in our other specialty’s national and international professional organizations including the American College of Allergy Asthma and Immunology, the World Allergy Organization, and the European Allergy Asthma and Immunology organization. I have been voted “Best Doctor” in Cincinnati since 1999 and have been ranked by US New and World Report as being in the top 1% of doctors in my specialty.
What separates our practice from ordinary allergy immunology practices? Simply put, our extensive expertise. Dr. Jonathan Bernstein is the co-director of the Cincinnati American Initiative In Mast Cell Diseases (AIM) center of excellence and our practice is a referral center from the Mast Cell Society patient advocacy organization and is considered a world expert in mast cell disorders with our without dysautonomia. Dr. Jonathan Bernstein is also the director of several registered centers of excellence including the Cincinnati Urticaria Center of Reference and Excellence (UCARE), the Angioedema Center of Reference and Excellence (ACARE), Atopic Dermatitis Center of Reference and Excellence (ADCARE) and the anaphylaxis Center of Reference and Excellence (ANACARE). He is a member of the World Allergy Organization Board of Directors and co-director of the Cincinnati World Allergy Organization Center of Excellence and a member of Hereditary Angioedema Medical Advisory Board, the GINA council for dissemination of asthma guidelines, the Joint Task Force Council that generates guidelines for our specialty and a founding board member of We CU, a patient advocacy group for patients with chronic urticaria.
What conditions do we manage? Our physicians see routine Allergy/Immunology medical problems but also patients with complex unexplained problems. Our focus is to look at the whole patient rather than focus on a specific complaint they may present with as often allergic and immunologic disorders are associated with many other conditions that need to be addressed in order to successfully treat their primary condition.
These conditions include mast cell disorders, neuroimmune conditions, dysautonomia, immunodeficiencies, refractory chronic urticaria, angioedema, moderate to severe inflammatory skin disorders like atopic dermatitis and contact dermatitis, chronic itching, chronic cough, moderate to severe asthma with or without COPD, chronic allergic and non-allergic rhinitis, chronic sinusitis with or without nasal polyps, eosinophilic disorders, food and drug allergies or intolerances, women’s health issues like progesterone allergy, chronic candida vulvovaginitis and seminal plasma allergy, PANS/PANDAs and environmental issues including mold exposure in the home or workplace.
Why should I come to your practice? We care for patients referred from all over the United States who have difficult to treat conditions not resolved after seeing many different types of specialists. The patients we see have often been to numerous physicians and had surgical procedures or received costly ineffective medications without resolution of their clinical problems. We successfully manage these patients because our physicians have the extensive expertise to address these complex Allergic and Immunologic conditions.
We are committed to being your advocate by carefully listening to your problems in order to find solutions that will improve your health and daily quality of life. It is our privilege to be a physician healer that participates in your care.
Why concierge now? We had to transition to concierge medicine in order to continue providing the concentrated care needed to address your medical needs. By remaining as an established patient or becoming a new patient, you will have your problem(s) addressed expeditiously with the necessary follow up care required until we achieve our shared goal of you feeling better. Currently, poor reimbursement from Medicare and the Managed Health Care system makes it difficult to sustain this level of care that we currently provide. Our new system will allow immediate access to our physicians and reduce waiting times during appointments.
Academic title: Professor of Medicine Department of Internal Medicine Professor of – Division of Allergy & Immunology, University of Cincinnati, Cincinnati, OH
Education: University of Cincinnati College of Medicine
Residencies: Internal Medicine, Cleveland Clinic Hospital
Fellowships: Adult & Pediatric Allergy & Clinical Immunology, Northwestern University Medical Center
Board Certifications: American Board of Allergy & Immunology; American Board of Internal Medicine
Patient Testimonials
“It’s clear why Dr. Bernstein receives such excellent reviews. He listens with the intent of understanding your unique situation and provides a thorough explanation of how your symptoms will be addressed. He is clearly a leader in the field of allergy research and treatment.”
“Dr. Bernstein was extremely informative and took extra care and time to explain everything. He came up with a care plan that was very thorough. He was very knowledgeable about a widely unknown condition. He exceeded my expectations.”
Selected publications related to conditions we treat from over 500 citations:
Bernstein JA. Progestogen Sensitization: a Unique Female Presentation of Anaphylaxis. Curr Allergy Asthma Rep. 2020 Jan 28;20(1):4.
Shaker MS, Wallace DV, Golden DB, Oppenheimer J, Bernstein JA, et al. Anaphylaxis – a 2020 Practice Parameter Update, Systematic Review and GRADE Analysis. J Allergy Clin Immunol. 2020 Jan 27. pii: S0091-6749(20)30105-6.
Patel GB, Kern RC, Bernstein JA, et al. Current and Future Treatments of Rhinitis and Sinusitis. J Allergy Clin Immunol Pract. 2020 Jan 28. pii: S2213-2198(20)30071-4.
Lai Y, Zhang G, Zhou Z, Inhaber N, Bernstein JA, et al. A novel functional C1 inhibitor activity assay in dried blood spot for diagnosis of Hereditary angioedema. Clin Chim Acta. 2020 Feb 12;504:155-162.
Bernstein JA, et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2020 Feb 14. pii: S2213-2600(19)30372-8.
Leisman DE, Harhay MO, Lederer DJ, Abramson M, Adjei AA, Bakker J, Ballas ZK, Barreiro E, Bell SC, Bellomo R, Bernstein JA, et al. Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals. Crit Care Med. 2020 Mar 4.
Shaker MS, Oppenheimer J, Wallace DV, Golden DBK, Lang DM; Joint Task Force for Allergy Practice Parameters, Lang ES, Bernstein JA, et al. Making the GRADE in Anaphylaxis Management: Towards Recommendations Integrating Values, Preferences, Context, and Shared Decision-Making. Ann Allergy Asthma Immunol. 2020 Mar 18. pii: S1081-1206(20)30153-8.
Maurer M, Aberer W, Agondi R, Al-Ahmad M, Al-Nesf MA, Ansotegui I, Arnaout R, Arruda LK, Asero R, Aygören-Pürsün E, Banerji A, Bauer A, Ben-Shoshan M, Berardi A, Bernstein JA, et al. Definition, aims, and implementation of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy. 2020 Apr 5.
Saini S, Shams M, Bernstein JA, Maurer M. Urticaria and Angioedema across the ages. J Allergy Clin Immunol Pract. 2020 Apr 13. pii: S2213-2198(20)30329-9.
Hirano I, Chan ES, Rank MA, Sharaf RN, Stollman NH, Stukus DR, Wang K, Greenhawt M, Falck-Ytter YT,Chachu KA, Day L, Lebwohl B, Muniraj T, Patel A, Peery AF, Shah R, Singh H, Singh S, Spechler SJ, Sultan S, Su GL, Thrift AP, Weiss JM, Weizman AV, Bernstein JA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2020 May;124(5):416-423.
Mersha TB, Afanador Y, Johansson E, Proper SP, Bernstein JA, et al. Resolving Clinical Phenotypes into Endotypes in Allergy: Molecular and Omics Approaches. Clin Rev Allergy Immunol. 2020 May 6.
Cherrez-Ojeda I, Mata VL, Vanegas E, Felix M, Bernstein JA, et al. Influence of Generational Cohorts on the Preferences for Information and Communication Technologies in Latin American Patients with Obstructive Lung Diseases. Int J Telemed Appl. 2020 Jan 23;2020:2489890.
Morais-Almeida M, Aguiar R, Martin B, Ansotegui IJ, Ebisawa M, Arruda LK, Caminati M, Canonica GW, Carr T, Chupp G, Corren J, Dávila I, Park HS, Hanania NA, Rosenwasser L, Sánchez-Borges M, Virchow JC, Yáñez A, Bernstein JA, et al. COVID-19, asthma, and biologic therapies: What we need to know. World Allergy Organ J. 2020 May 16:100126.
Riedl MA, Maurer M, Bernstein JA, et al; HELP Investigators. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy. 2020 May 26.
Bernstein JA, et al. Long-term Safety and Efficacy of Subcutaneous C1-Inhibitor in Older Patients With Hereditary Angioedema. Ann Allergy Asthma Immunol. 2020 May 20:S1081-1206(20)30333-1.
González de Olano D, Cain WV, Bernstein JA, Akin C. Disease Spectrum of Anaphylaxis Disorders. J Allergy Clin Immunol Pract. 2023 May 21:S2213-2198(23)00548-2.
Grumach AS, Gadir N, Kessel A, Yegin A, Martinez-Saguer I, Bernstein JA. Current challenges and future opportunities in patient-focused management of hereditary angioedema: A narrative review. Clin Transl Allergy. 2023 May;13(5):e12243.
Bernstein JA, et al. Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria. J Clin Med. 2023 May 19;12(10):3561.
Tiotiu A, Bikov A, Gonzalez-Barcala FJ, Novakova S, Novakova P, Chong-Neto H, Santus P, Ansotegui I, Ivancevich JC, Kowal K, Mihaicuta S, Nedeva D, Canonica GW, Bernstein JA, Boulet LP, Braido F. Criteria to evaluate efficacy of biologics in asthma: a Global Asthma Association survey. Expert Rev Respir Med. 2023 Jun 26:1-10.
Armstrong AW, Soong W, Bernstein JA. Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success. Dermatol Ther (Heidelb). 2023 Jun 24.
de Kam PJ, Zielen S, Bernstein JA, et al. Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy. Allergy. 2023 Jun 27.
Bernstein JA, et al. Chronic Urticaria and Angioedema: Masqueraders and Misdiagnoses. J Allergy Clin Immunol Pract. 2023 Jun 26:S2213-2198(23)00698-0.
Peters AT, Wagenmann M, Bernstein JA, et al. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis. Allergy Asthma Proc. 2023 Jul 1;44(4):265-274.
Yedidi RS, Bernstein JA. Recall Urticaria with Infusion of Agalsidase Beta. Ann Allergy Asthma Immunol. 2023 Aug 7:S1081-1206(23)00563-X.
Hardin H, Shao W, Bernstein JA. An Updated Review of PANDAS/PANS Disease Also Known as Idiopathic Autoimmune Encephalitis: What the Allergist Should Know. Ann Allergy Asthma Immunol. 2023 Aug 25:S1081-1206(23)00628-2.
Bernstein JA, et al. Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review. Adv Ther. 2023 Sep 12.
Wiffen L, D’Cruz LG, Brown T, Higenbottam TW, Bernstein JA, et al. Clinical severity classes in COVID-19 pneumonia have distinct immunological profiles, facilitating risk stratification by machine learning. Front Immunol. 2023 Sep 5;14:1192765.
Cohn DM, Aygören-Pürsün E, Bernstein JA, et al. Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat. Clin Transl Allergy. 2023 Sep;13(9):e12288.
Bellanti JA, Novak P, Faitelson Y, Bernstein JA, Castells MC. The Long Road of Long COVID: Specific Considerations for the Allergist and Immunologist. J Allergy Clin Immunol Pract. 2023 Sep 27:S2213-2198(23)01045-0.
Casale TB, Gimenez-Arnau AM, Bernstein JA, et al. Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status. Dermatol Ther (Heidelb). 2023 Sep 30.
Iding J, Agarwal P, Zhang S, Odin R, Bernstein JA, Zimmermann N. Standardized quantification of mast cells in the gastrointestinal tract in adults. J Allergy Clin Immunol Pract. 2023 Oct 31:S2213-2198(23)01200-X.
Bernstein JA, et al. Real-world unified airway benefits of mepolizumab: Effectiveness in patients with asthma and comorbid nasal polyps. Ann Allergy Asthma Immunol. 2024 Jul 6:S1081-1206(24)00421-6.
Craig T, Tachdjian R, Bernstein JA, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents. Ann Allergy Asthma Immunol. 2024 Aug 9:S1081-1206(24)00489-7.
Bernstein JA, et al. Patient-Reported Outcome Measures in Chronic Spontaneous Urticaria, Angioedema, and Atopic Dermatitis. J Allergy Clin Immunol Pract. 2024 Aug 19:S2213-2198(24)00840-7.
Casale TB, Trzaskoma B, Holden M, Bernstein JA, Maurer M. Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab? World Allergy Organ J. 2024 Aug 5;17(8):100943.
Nochaiwong S, Chuamanochan M, Ruengorn C, Awiphan R, Bernstein JA, Thavorn K. Cost and Cost-Effectiveness of the Management Strategies of Chronic Urticaria: A Systematic Review. JAMA Dermatol. 2024 Aug 28.
Martin Nguyen A, La Rosa C, Cornell AG, Sher MR, Bernstein JA, et al. Content validity of the Leicester Cough Questionnaire in adults with refractory or unexplained chronic cough: a qualitative interview study. Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241274261. Bernstein JS, Bernstein JA, Lang DM. Chronic Spontaneous Urticaria: Current and Emerging Biologic Agents. Immunol Allergy Clin North Am. 2024 Nov;44(4):595-613.
Jakymec YA, Greiwe J, Bernstein JA. Immunotherapy and new treatments. Curr Opin Allergy Clin Immunol. 2024 Sep 20.
Reshef A, Hsu C, Katelaris CH, Li PH, Magerl M, Yamagami K, Guilarte M, Keith PK, Bernstein JA, Lawo JP, Shetty H, Pollen M, Wieman L, Craig TJ; VANGUARD Study Group. Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study. Allergy. 2024 Oct 7.
Bernstein JS, Bernstein JA, Lang DM. Chronic Spontaneous Urticaria: Current and Emerging Biologic Agents. Immunol Allergy Clin North Am. 2024 Nov;44(4):595-613.
Lang DM, Sheikh J, Joshi S, Bernstein JA. Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: Evolving toward personalized medicine. Ann Allergy Asthma Immunol. 2024 Oct 26:S1081-1206(24)01633-8.
Odin R, Anderson J, Jacobs J, Jones D, Li HH, Lumry W, Manning M, Soteres D, Tachdjian R, Yang W, Bernstein JA. The utility of shared decision making in the management of hereditary angioedema. Allergy Asthma Proc. 2024 Nov 1;45(6):434-437.

